First Time Loading...

NeuroMetrix Inc
NASDAQ:NURO

Watchlist Manager
NeuroMetrix Inc Logo
NeuroMetrix Inc
NASDAQ:NURO
Watchlist
Price: 4.25 USD 2.16% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

NURO doesn't have a meaningful market cap.

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. [ Read More ]

The intrinsic value of one NURO stock under the Base Case scenario is 9.26 USD. Compared to the current market price of 4.25 USD, NeuroMetrix Inc is Undervalued by 54%.

Key Points:
NURO Intrinsic Value
Base Case
9.26 USD
Undervaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
NeuroMetrix Inc

Backtest NURO Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NURO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of NeuroMetrix Inc's business.

What risks and challenges
does NeuroMetrix Inc face in the near future?

Summarize the latest earnings report
of NeuroMetrix Inc.

Provide P/E
for NeuroMetrix Inc and its competitors.

Financials

Balance Sheet Decomposition
NeuroMetrix Inc

Current Assets 20.7m
Cash & Short-Term Investments 17.6m
Receivables 610k
Other Current Assets 2.5m
Non-Current Assets 580k
PP&E 550k
Other Non-Current Assets 30k
Current Liabilities 1.3m
Accounts Payable 230k
Accrued Liabilities 1m
Non-Current Liabilities 120k
Other Non-Current Liabilities 120k
Efficiency

Earnings Waterfall
NeuroMetrix Inc

Revenue
6.4m USD
Cost of Revenue
-2.1m USD
Gross Profit
4.3m USD
Operating Expenses
-10.5m USD
Operating Income
-6.2m USD
Other Expenses
580k USD
Net Income
-5.6m USD

Free Cash Flow Analysis
NeuroMetrix Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

NURO Profitability Score
Profitability Due Diligence

NeuroMetrix Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Negative 3-Years Revenue Growth
Negative 1-Year Revenue Growth
21/100
Profitability
Score

NeuroMetrix Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

NURO Solvency Score
Solvency Due Diligence

NeuroMetrix Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

NeuroMetrix Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NURO Price Targets Summary
NeuroMetrix Inc

There are no price targets for NURO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

NURO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

NURO Price
NeuroMetrix Inc

1M 1M
+5%
6M 6M
-26%
1Y 1Y
-64%
3Y 3Y
-84%
5Y 5Y
-95%
10Y 10Y
-100%
Annual Price Range
4.25
52w Low
2.94
52w High
11.84
Price Metrics
Average Annual Return -24.53%
Standard Deviation of Annual Returns 59.03%
Max Drawdown -99%
Shares Statistics
Market Capitalization 8.4m USD
Shares Outstanding 1 986 540
Percentage of Shares Shorted 2.19%

NURO Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

NeuroMetrix Inc Logo
NeuroMetrix Inc

Country

United States of America

Industry

Health Care

Market Cap

8.4m USD

Dividend Yield

0%

Description

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. The company is headquartered in Waltham, Massachusetts and currently employs 23 full-time employees. The company went IPO on 2004-07-22. The firm is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. The company has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Contact

MASSACHUSETTS
Waltham
1000 Winter St
+17818909989.0
http://www.neurometrix.com/

IPO

2004-07-22

Employees

23

Officers

Founder, Chairman, CEO, President & Secretary
Dr. Shai N. Gozani M.D., Ph.D.
Senior VP, CFO & Treasurer
Mr. Thomas T. Higgins
Chief Data Scientist
Dr. Xuan Kong Ph.D.
Senior Vice President of Population Health & Value Based Care
Ms. Susan M. Bell R.N.

See Also

Discover More
What is the Intrinsic Value of one NURO stock?

The intrinsic value of one NURO stock under the Base Case scenario is 9.26 USD.

Is NURO stock undervalued or overvalued?

Compared to the current market price of 4.25 USD, NeuroMetrix Inc is Undervalued by 54%.